ClinicalTrials.gg
RecruitingNCT06281899PRODAPA-CKDUpdated Oct 28, 2026

Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Dapagliflozin 10 mg Tab and Low protein diet in Chronic Kidney Diseases and Type 2 Diabetes Mellitus, sponsored by Anemia Working Group Romania. Recruiting at 1 site in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Anemia Working Group Romania · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jan 2022, registered Feb 2024).
  • Started Jan 2022; still recruiting 4 years 10 months later.
Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Renal Insufficiency, Chronic with a site in Romania — 8 open to participants now, 11 under way, 7 of them phase 3. Renal Insufficiency, Chronic · Romania.

Planned enrollment
37th of 56
200 · median 455
Started
2022
with 1 other
Phase 4
4 of 65
1 open now
Primary completion
2027-12
later than 3 of 10 live
Registered
53rd of 65
by date
Lead sponsor
4 of 65
Anemia Working Group Romania

Among the 65 studies in Renal Insufficiency, Chronic with a site in Romania, this one is the 37th largest by planned enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 4, reaches primary completion later than 3 of the 10 other live ones, and was the 53rd registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

8 of the 65 studies in Renal Insufficiency, Chronic with a site in Romania are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Renal Insufficiency, Chronic with a site in Romania, or all of them as a file.
02

Study summary

This is a prospective multicenter randomized controlled trial with a total duration of 36 months aiming to evaluate the effectiveness and the safety of low protein diet on top of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and renin-angiotensin-aldosterone inhibitors (RAASi) in reducing the progression of chronic kidney disease in patients with type 2 Diabetes Mellitus

Read the detailed description

The KDIGO Diabetes in CKD Guideline (2020) recommends the use of SGLT2i (level 1A) and suggests (level 2C) the prescription of plant protein-based low-protein diet in patients with chronic kidney disease (CKD) and diabetes mellitus (DM). Both interventions have shown synergistic nephroprotective effects, slowing the progression of chronic kidney disease by reducing glomerular hyperfiltration and proteinuria, thus resulting the hypothesis that by combining these two interventions it could be possible to achieve a superior control over the progression of diabetic kidney disease.

The nutritional intervention will consist in a mild protein restriction (0.6 g/kg dry ideal body weight) and a total recommended energy intake of 30-35 kcal/kg of ideal dry body weight per day in all patients. The protein intake will be checked through the food diary and calculated based on urea from 24 hours urine collection.

The efficacy and safety parameters will be evaluated during follow-up visits at month 1,2,3,6,12 and 18.

03

Conditions studied

  • Chronic Kidney Diseases
  • Type 2 Diabetes Mellitus

Keywords

  • chronic kidney disease
  • low protein diet
  • nutrition therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age>18 years old
  • confirmed chronic kidney disease (with between 60 and 20 ml/min/1.73 m2 and/or proteinuria >500 mg/g urinary creatinine) and confirmed type 2 Diabetes Mellitus
  • stable kidney function for at least 12 weeks before enrollment (defined as decrease in eGFR \< 5 ml/min/1.73 m2/year according to KDIGO 2012 guideline)
  • treatment with ACE/ARBs and/or MRAs for at least 3 months
  • no previous treatment with SGLT2i
  • good nutritional status
  • declared and anticipated good compliance with the prescribed diet
  • signed

Exclusion criteria

Exclusion Criteria:

  • \< 25 ml/min/1.73 m2
  • poorly controlled arterial blood pressure (mean BP≥145/85 mm Hg)
  • class IV heart failure, recent MACE (less than 6 months)
  • relevant comorbid conditions (active infections (, , ), active neoplasia, digestive diseases with malabsorption, active diseases/ therapy)
  • ADPKD
  • kidney transplantation with functional graft
  • malnutrition: \<18 kg/me, eight loss >10% during the last 6 months, serum albumin \<3 g/dL
  • feeding inability (anorexia, nausea)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Intervention

    Patients will receive a plant-based low protein diet (0.6 g proteins/kg ideal body weight per day) associated with Dapagliflozin 10 mg per day

    Drug: Dapagliflozin 10 mg Tab · Behavioral: Low protein diet

  • Active comparator
    Control

    Patients will receive Dapagliflozin 10 mg per day

    Drug: Dapagliflozin 10 mg Tab

Interventions

06

What researchers measure

Primary outcomes

  1. Time to the First Occurrence of Any of the Components of the Composite: ≥30% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death

    End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a kidney transplant

    Time frame: 12 months after randomization

Secondary outcomes

  1. Rate of decline in the estimated Glomerular Filtration Rate

    Difference between eGFR at any timepoint and the initial eGFR

    Time frame: month 3, 9 and12 after randomization

  2. Variation of albuminuria

    Difference between albuminuria at at any timepoint and the initial albuminuria (expressed as albumin to creatinine ratio)

    Time frame: month 3, 9 and12 after randomization

  3. Variation of HbA1C

    Difference between HbA1C at at any timepoint and the initial HbA1C

    Time frame: month 3, 9 and12 after randomization

  4. Variation of serum cholesterol levels

    Difference between serum cholesterol at at any timepoint and the initial serum cholesterol

    Time frame: month 3, 9 and12 after randomization

  5. Variation of serum bicarbonate levels

    Difference between serum bicarbonate at at any timepoint and the initial serum bicarbonate

    Time frame: month 3, 9 and12 after randomization

  6. Variation of serum potassium levels

    Difference between serum potassium at at any timepoint and the initial serum potassium

    Time frame: month 3, 9 and12 after randomization

  7. Variation of serum sodium levels

    Difference between serum sodium at at any timepoint and the initial serum sodium

    Time frame: month 3, 9 and12 after randomization

  8. Variation of hemoglobin levels

    Difference between hemoglobin at at any timepoint and the initial serum hemoglobin

    Time frame: month 3, 9 and12 after randomization

  9. Variation of hematocrit levels

    Difference between hematocrit at at any timepoint and the initial hematocrit

    Time frame: month 3, 9 and12 after randomization

  10. All cause hospitalizations

    Percentage of patients who experienced hospitalizations of all cause

    Time frame: 12 months after randomization

  11. Variation in body weight

    Difference between body weight at at any timepoint and the body weight

    Time frame: month 3, 9 and12 after randomization

  12. Variation in BMI

    Difference between BMI at at any timepoint and the initial BMI

    Time frame: month 3, 9 and12 after randomization

  13. Variation in handgrip strength

    Difference between handgrip strength at at any timepoint and the initial handgrip strength

    Time frame: month 3, 9 and12 after randomization

  14. Variation in serum albumin levels

    Difference between serum albumin at at any timepoint and the initial serum albumin

    Time frame: month 3, 9 and12 after randomization

  15. Variation in CRP levels

    Difference between CRP at at any timepoint and the initial CRP

    Time frame: month 3, 9 and12 after randomization

  16. Changes in the quality of life

    Evaluated by SF-36 questionaire

    Time frame: month 3, 9 and12 after randomization

Other outcomes

  1. Compliance to the protein intake

    Achieved protein intake will be estimated based on urinary urea excretion, using Mitch-Maroni's formula

    Time frame: month 1, 3, 9 and12 after randomization

  2. Compliance to the energy intake

    Achieved energy intake will be estimated using the 3-day food diary to calculate the daily energy intake

    Time frame: month 1, 3, 9 and12 after randomization

  3. Compliance to carbohydrate intake

    Achieved energy intake will be estimated by the 3-day food diary to calculate thecarbohydrates intake

    Time frame: month 1, 3, 9 and12 after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2027, 71 months after the start.

Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's planned 71 months is above that.

Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2024 → Dec 2027 and completion Mar 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2024
First posted
Feb 28, 2024
StartActual
Jan 1, 2022
Primary completionEst.
Dec 31, 2027was Dec 2024
CompletionEst.
Dec 31, 2027was Mar 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2024→Dec 31, 2027
Oct 28, 2026
Study completion
Mar 31, 2025→Dec 31, 2027
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion Dec 31, 2024→Dec 31, 2027
    Study completion Mar 31, 2025→Dec 31, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06281899
Lead sponsor
Anemia Working Group Romania
Collaborators
Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania, Dr Carol Davila Teaching Hospital of Nephrology, Nephrology Department, Bucharest, Romania, Carol Davila University of Medicine and Pharmacy
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Jan 1, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Liliana Garneata, Professor
Contact
lilianagarna@yahoo.com
+40722619358
Elena Cuiban, PhD student
Contact
elena.cuiban@drd.umfcd.ro
+40748975315
Liliana Garneata, Professor
principal investigator · Carol Davila University of Medicine and Pharmacy Bucharest, Romania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion